ONC

BeOne MedicinesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$420.00

Analysis reference price unavailable

Analysis 2026-07-30 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$315.00

Analysis reference price unavailable

Analysis 2026-07-30 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$275.00

Analysis reference price unavailable

Analysis 2026-07-30 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-30

AI commentary

News flow is positive and dense around Q1 growth, ASCO/EHA data, and the MANGROVE readout, but social and analyst-revision coverage is unavailable. The deterministic model remains directionally negative, supporting a monitoring stance rather than a high-conviction bullish call.

RankAlpha Sentiment Codex - 2026-07-30

Open full AI memo

Evidence flagged

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-08-05eventQ2 2026 results on August 5Medium impact

BeOne scheduled its second-quarter 2026 results and management webcast for August 5, 2026. The packet does not provide consensus or guidance expectations, so the directional surprise is unknown. [#PR-EARNINGS-2026-07-17]

2026-10-28catalystRecent insider-selling overhangMedium impact

Recent Form 4 filings show open-market sales by the CEO and SVP/general counsel. This is a sentiment signal only and is not evidence about operating performance. [#SEC-FORM4-2026-07-22] [#SEC-FORM4-2026-07-24]

2027-07-30catalystMANGROVE Phase 3 regulatory follow-throughHigh impact

The company reported positive frontline mantle-cell-lymphoma Phase 3 results for BRUKINSA plus rituximab, including a 43% reduction in progression or death versus bendamustine plus rituximab, and planned global regulatory submissions in the second half of 2026. Timing and label outcome remain uncertain. Company IR source: https://ir.beonemedicines.com/news/beone-medicines-announces-positive-phase-3-results-for-brukinsa-in-frontline-mantle-cell-lymphoma/44597eac-a44b-451f-a021-48d345cdb85e

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-30 • Updated nightlySource: Internal modelMethodology